Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C – real-world data from the German observational, prospective, nation-wide CRISP Registry (AIO-TRK-0315) 5. November 2020 Griesinger F, Eberhardt WEE2, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Jänicke M, Fleitz A, Zacharias S, Hipper A, Buller M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Sebastian M, Thomas M, 2020 Download What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL A. Welt, M. Thill, E. Stickeler, M.-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Weiterlesen 1st-line Panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany – Interim results of the non-interventional study VALIDATE J. Uhlig, J. Potenberg, D. Semsek, P. Stübs, C. Fichter, A. Köhler, L. Müller, M. Reiser, H.U. Siebenbach, T. Göhler, L. Jacobasch, V. Kächele, B. Weiterlesen